Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced… Read More
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer,… Read More
Acquisition aims to provide broader access to comprehensive testing and laboratory services for patients and physicians in North Mississippi BURLINGTON, NC – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory… Read More
Building on the last approval of Jemperli offering PFS benefit in dMMR/MSI-HC endometrial cancer, the expanded indication now offers survival benefit across the overall study population (dMMR/MSI-H and MMRp/MSS tumours) Approval based… Read More
